CBY2

Across TCGA pan-cancer cohorts, CBY2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CBY2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CBY2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CBY2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, STAD, and KICH are the cancer types where CBY2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.170	0.802	<.001	24	view →
STAD	OS	Median	All	0.184	0.730	.002	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
KIRP	DFS	Median	All	0.595	0.919	.005	12	view →
LUAD	OS	Median	All	0.427	0.688	.006	9	view →
COAD	OS	Median	III,IV	0.449	0.797	.029	6	view →
LIHC	DFS	Median	II,III,IV	0.083	0.427	.028	6	view →
UCEC	DFS	Median	All	1.000	0.635	.032	4	view →
LGG	DFS	Median	All	0.201	0.728	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CBY2–LUSC (DFS)

Open the LUSC breakdown →